Markets & Investing
U.S. Government Announces $1.5 Million Grant For Psychedelics Research
Support for psychedelic research continues to gain acceptance at the federal level as the National Institute on Drug Abuse (NIDA) announces a funding grant…
Support for psychedelic research continues to gain acceptance at the federal level as the National Institute on Drug Abuse (NIDA) announces a funding grant for research proposals of psychedelic medicine.
Advancing Psychedelics Research for Treating Addiction (R61/R33 Clinical Trial Required) https://t.co/kr3xqmsJGM
— NIH Funding (@NIHFunding) May 16, 2023
Under the Department of Health and Human Services and the National Institutes of Health (NIH), three notices of funding opportunities were published this week, calling for submissions of research projects focused on how psychedelics could be used for substance use disorders (SUDs).
The government agencies are seeking proposals and research initiatives into the treatment of drug addiction using psychedelics, with an allocated $1.5 million in funding.
Click here for a complete look at the announcement and call for submission.
For more on federal support for psychedelics, see Bipartisan Group Pushes Congress for Psychedelic Research
The post U.S. Government Announces $1.5 Million Grant For Psychedelics Research appeared first on Microdose.
psychedelics psychedelic funding research
-
Psychedelics1 week agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics1 week agoRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation1 week agoTryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week agoSilo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week agoPsilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID